BellRing Brands, Inc.
—- Market cap
- —
- Debt
- —
- Cash
- −$71.80M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BRBR stock price vs JAZZ: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at JAZZ's multiple
Needs JAZZ P/E.
Implied fair value · at BRBR's multiple
Needs Annual EPS is negative, BRBR P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BellRing Brands, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Jazz Pharmaceuticals plc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
HERBALIFE LTD.
BRBR vs HLF
Simply Good Foods Co
BRBR vs SMPL
HORMEL FOODS CORP /DE/
BRBR vs HRL
Post Holdings, Inc.
BRBR vs POST
GENERAL MILLS INC
BRBR vs GIS
AMGEN INC
BRBR vs AMGN
GILEAD SCIENCES, INC.
BRBR vs GILD
VERTEX PHARMACEUTICALS INC / MA
BRBR vs VRTX
SUPERNUS PHARMACEUTICALS, INC.
BRBR vs SUPN
Vanda Pharmaceuticals Inc.
BRBR vs VNDA
PERRIGO Co plc
BRBR vs PRGO
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BRBR can sustain its current 16.1% revenue growth and 15.4% operating margin, then BRBR looks attractive relative to JAZZ because it is priced at only 0.6x sales versus JAZZ at 3.7x while also generating positive earnings and higher ROIC.
BRBR trades at 0.6x P/S and 5.9x EV/EBITDA versus JAZZ at 3.7x P/S and 63.1x EV/EBITDA, so the valuation gap is wide on both sales- and earnings-based measures. The implied price of $72.19 suggests substantial rerating potential versus BRBR's current price of $12.66, which sits near the bottom of its historical band.
Supporting Metrics